Is soluble fms-like tyrosine kinase 1 increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates : relationship to circulating placental growth factor?
These data are consistent with a role for sFlt-1 in the maternal manifestations of preeclampsia. In contrast to preeclampsia, sFlt-1 does not appear to contribute substantially to decreased circulating free PlGF in SGA pregnancies in the absence of a maternal syndrome.
Simvastatin may prove clinically significant in suppressing the development and expansion of AAAs and, thereby, in reducing the risk of rupture and the need for repair.